358 related articles for article (PubMed ID: 10930144)
1. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.
Mallal SA; John M; Moore CB; James IR; McKinnon EJ
AIDS; 2000 Jul; 14(10):1309-16. PubMed ID: 10930144
[TBL] [Abstract][Full Text] [Related]
2. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.
Nolan D; Hammond E; James I; McKinnon E; Mallal S
Antivir Ther; 2003 Dec; 8(6):617-26. PubMed ID: 14760896
[TBL] [Abstract][Full Text] [Related]
3. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.
Saint-Marc T; Partisani M; Poizot-Martin I; Bruno F; Rouviere O; Lang JM; Gastaut JA; Touraine JL
AIDS; 1999 Sep; 13(13):1659-67. PubMed ID: 10509567
[TBL] [Abstract][Full Text] [Related]
4. Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy.
Mulligan K; Tai VW; Algren H; Abrams DI; Leiser RJ; Lo JC; Schambelan M
J Acquir Immune Defic Syndr; 2001 Apr; 26(5):443-8. PubMed ID: 11391163
[TBL] [Abstract][Full Text] [Related]
5. Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors.
Schweinsburg BC; Taylor MJ; Alhassoon OM; Gonzalez R; Brown GG; Ellis RJ; Letendre S; Videen JS; McCutchan JA; Patterson TL; Grant I;
J Neurovirol; 2005 Aug; 11(4):356-64. PubMed ID: 16206458
[TBL] [Abstract][Full Text] [Related]
6. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
7. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.
Dubé MP; Komarow L; Mulligan K; Grinspoon SK; Parker RA; Robbins GK; Roubenoff R; Tebas P;
J Acquir Immune Defic Syndr; 2007 Aug; 45(5):508-14. PubMed ID: 17589373
[TBL] [Abstract][Full Text] [Related]
8. Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
Duvivier C; Ghosn J; Assoumou L; Soulié C; Peytavin G; Calvez V; Génin MA; Molina JM; Bouchaud O; Katlama C; Costagliola D;
J Antimicrob Chemother; 2008 Oct; 62(4):797-808. PubMed ID: 18641035
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis.
Lonergan JT; Barber RE; Mathews WC
AIDS; 2003 Nov; 17(17):2495-9. PubMed ID: 14600521
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.
Buffet M; Schwarzinger M; Amellal B; Gourlain K; Bui P; Prévot M; Deleuze J; Morini JP; Gorin I; Calvez V; Dupin N
J Clin Virol; 2005 May; 33(1):60-4. PubMed ID: 15797366
[TBL] [Abstract][Full Text] [Related]
11. Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care.
Crane HM; Grunfeld C; Willig JH; Mugavero MJ; Van Rompaey S; Moore R; Rodriguez B; Feldman BJ; Lederman MM; Saag MS; Kitahata MM
AIDS; 2011 Jan; 25(2):185-95. PubMed ID: 21150555
[TBL] [Abstract][Full Text] [Related]
12. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
[TBL] [Abstract][Full Text] [Related]
13. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
van der Valk M; Gisolf EH; Reiss P; Wit FW; Japour A; Weverling GJ; Danner SA;
AIDS; 2001 May; 15(7):847-55. PubMed ID: 11399957
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients.
Pace CS; Martin AM; Hammond EL; Mamotte CD; Nolan DA; Mallal SA
Antivir Ther; 2003 Aug; 8(4):323-31. PubMed ID: 14518702
[TBL] [Abstract][Full Text] [Related]
15. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.
Jones SP; Qazi N; Morelese J; Lebrecht D; Sutinen J; Yki-Jărvinen H; Back DJ; Pirmohamed M; Gazzard BG; Walker UA; Moyle GJ
J Acquir Immune Defic Syndr; 2005 Dec; 40(5):565-72. PubMed ID: 16284533
[TBL] [Abstract][Full Text] [Related]
16. Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor.
Domingo P; Sambeat MA; Pérez A; Ordoñez J; Rodriguez J; Vázquez G
Antivir Ther; 2003 Jun; 8(3):223-31. PubMed ID: 12924539
[TBL] [Abstract][Full Text] [Related]
17. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
[TBL] [Abstract][Full Text] [Related]
18. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.
John M; McKinnon EJ; James IR; Nolan DA; Herrmann SE; Moore CB; White AJ; Mallal SA
J Acquir Immune Defic Syndr; 2003 May; 33(1):29-33. PubMed ID: 12792352
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy.
Nolan D; Hammond E; Martin A; Taylor L; Herrmann S; McKinnon E; Metcalf C; Latham B; Mallal S
AIDS; 2003 Jun; 17(9):1329-38. PubMed ID: 12799554
[TBL] [Abstract][Full Text] [Related]
20. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy.
Gervasoni C; Ridolfo AL; Trifirò G; Santambrogio S; Norbiato G; Musicco M; Clerici M; Galli M; Moroni M
AIDS; 1999 Mar; 13(4):465-71. PubMed ID: 10197374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
